Nivolumab联合Brentuximab Vedotin与单独Brentuximab Vedotin在复发难治性或不适合自体干细胞移植(ASCT)的晚期经典霍奇金淋巴瘤患者中的随机、开放、3期试验(Checkmate 812: Checkpoint Pathway and Nivolumab Clinical Trial Evaluation 812)